|
||||||||||||||||||||||||||
| SEC Info℠ | | | Home | | | Search | | | My Interests | | | Help | | | Sign In | | | Please Sign In | |||||||
|
||||||||||||||||||||||||||
As Of Filer Filing For·On·As Docs:Size Issuer Filing Agent 2/26/20 Sarepta Therapeutics, Inc. 10-K 12/31/19 129:25M ActiveDisclosure/FA |
Document/Exhibit Description Pages Size
1: 10-K 2019 Form 10-K HTML 2.41M
2: EX-4.4 Instrument Defining the Rights of Security Holders HTML 46K
3: EX-10.51 Material Contract HTML 787K
4: EX-10.52 Material Contract HTML 169K
5: EX-10.53 Material Contract HTML 725K
6: EX-10.54 Material Contract HTML 224K
7: EX-10.55 Material Contract HTML 51K
8: EX-10.56 Material Contract HTML 50K
9: EX-10.57 Material Contract HTML 39K
10: EX-21.1 Subsidiaries List HTML 33K
11: EX-23.1 Consent of Experts or Counsel HTML 37K
12: EX-31.1 Certification -- §302 - SOA'02 HTML 39K
13: EX-31.2 Certification -- §302 - SOA'02 HTML 39K
14: EX-32.1 Certification -- §906 - SOA'02 HTML 37K
15: EX-32.2 Certification -- §906 - SOA'02 HTML 37K
121: R1 Document and Entity Information HTML 99K
49: R2 Consolidated Balance Sheets HTML 118K
36: R3 Consolidated Balance Sheets (Parenthetical) HTML 53K
78: R4 Consolidated Statements of Operations and HTML 101K
Comprehensive Loss
120: R5 Consolidated Statements of Stockholders' Equity HTML 104K
48: R6 Consolidated Statements of Cash Flows HTML 181K
35: R7 Organization and Nature of Business HTML 40K
77: R8 Summary of Significant Accounting Policies and HTML 121K
Recent Accounting Pronouncements
122: R9 License and Collaboration Agreements HTML 106K
30: R10 Gain From Sale of Priority Review Voucher HTML 36K
70: R11 Fair Value Measurements HTML 183K
114: R12 Cash, Cash Equivalents and Marketable Securities HTML 190K
98: R13 Accounts Receivable and Reserves for Product Sales HTML 136K
31: R14 Inventory HTML 56K
71: R15 Other Assets HTML 103K
115: R16 Property and Equipment, Net HTML 84K
99: R17 Intangible Assets HTML 83K
32: R18 Accrued Expenses HTML 76K
69: R19 Indebtedness HTML 110K
118: R20 Equity HTML 39K
74: R21 Stock-Based Compensation HTML 548K
37: R22 401 (K) Plan HTML 38K
50: R23 Other (Loss) Income HTML 73K
119: R24 Income Taxes HTML 298K
75: R25 Leases HTML 106K
38: R26 Net Loss Per Share HTML 70K
51: R27 Commitments and Contingencies HTML 76K
117: R28 Subsequent Event HTML 38K
76: R29 Financial Information by Quarter (Unaudited) HTML 320K
97: R30 Summary of Significant Accounting Policies and HTML 183K
Recent Accounting Pronouncements (Policies)
112: R31 Summary of Significant Accounting Policies and HTML 47K
Recent Accounting Pronouncements (Tables)
73: R32 License and Collaboration Agreements (Tables) HTML 65K
34: R33 Fair Value Measurements (Tables) HTML 180K
95: R34 Cash, Cash Equivalents and Marketable Securities HTML 190K
(Tables)
111: R35 Accounts Receivable and Reserves for Product Sales HTML 139K
(Tables)
72: R36 Inventory (Tables) HTML 58K
33: R37 Other Assets (Tables) HTML 105K
94: R38 Property and Equipment, Net (Tables) HTML 84K
113: R39 Intangible Assets (Table) HTML 82K
85: R40 Accrued Expenses (Tables) HTML 75K
128: R41 Indebtedness (Tables) HTML 99K
53: R42 Stock-Based Compensation (Tables) HTML 557K
41: R43 Other (Loss) Income (Tables) HTML 73K
84: R44 Income Taxes (Tables) HTML 298K
127: R45 Leases (Tables) HTML 109K
52: R46 Net Loss Per Share (Tables) HTML 70K
39: R47 Commitments and Contingencies (Tables) HTML 51K
83: R48 Financial Information by Quarter (Unaudited) HTML 320K
(Tables)
129: R49 Organization and Nature of Business - Additional HTML 49K
Information (Detail)
109: R50 Summary of Significant Accounting Policies and HTML 78K
Recent Accounting Pronouncements - Additional
Information (Detail)
90: R51 Summary of Estimated Useful Lives of Plant and HTML 60K
Equipment (Detail)
22: R52 License and Collaboration Agreements - Additional HTML 325K
Information (Detail)
60: R53 Schedule of Total Consideration of Business HTML 66K
Acquisition (Details)
110: R54 Gain From Sale of Priority Review Voucher - HTML 39K
Additional Information (Detail)
91: R55 Assets and Liabilities Measured and Carried at HTML 71K
Fair Value (Detail)
23: R56 Summary of Company Financial Assets with HTML 43K
Maturities of Less Than 90 Days Included in Cash
Equivalents (Detail)
61: R57 Cash, Cash Equivalents and Marketable Securities - HTML 36K
Additional Information (Detail)
107: R58 Summary of Company Cash, Cash Equivalents and HTML 82K
Investments (Detail)
93: R59 Summary of Components of Accounts Receivable HTML 43K
(Detail)
43: R60 Summary of Change in Reserves for Discounts and HTML 54K
Allowances (Detail)
57: R61 Summary of Total Reserves Included in Consolidated HTML 41K
Balance Sheets (Detail)
124: R62 Inventory - Summary of Components of Inventory HTML 47K
(Detail)
80: R63 Summary of Other Current Assets (Detail) HTML 54K
44: R64 Summary of Other Non-current Assets (Detail) HTML 50K
58: R65 Summarizes Components of Property and Equipment, HTML 64K
Net (Detail)
125: R66 Property and Equipment, Net - Additional HTML 37K
Information (Detail)
81: R67 Intangible Assets - Summary of Components of HTML 48K
Intangible Assets (Detail)
47: R68 Intangible Assets - Additional Information HTML 70K
(Detail)
55: R69 Intangible Assets - Summary of Estimated Future HTML 50K
Amortization for Intangible Assets (Detail)
65: R70 Summary of Accrued Expenses (Detail) HTML 58K
28: R71 Indebtedness - Additional Information (Detail) HTML 143K
88: R72 Indebtedness - Summary of Debt Facilities (Detail) HTML 57K
102: R73 Indebtedness - Summarizes Total Gross Payments Due HTML 42K
under Company's Debt Arrangements (Detail)
64: R74 Equity - Additional Information (Detail) HTML 55K
27: R75 Stock Based Compensation - Additional Information HTML 153K
(Detail)
87: R76 Assumptions for Measuring Fair Values of Stocks HTML 58K
(Detail)
101: R77 Assumptions for Measuring Fair Values of Stocks HTML 36K
(Parenthetical) (Detail)
67: R78 Summary of Stock Option Activity (Detail) HTML 92K
24: R79 Summary of Stock Option Activity (Parenthetical) HTML 45K
(Detail)
66: R80 Summary of Company's Stock Options Vested and HTML 39K
Exercised (Detail)
29: R81 Summary of Restricted Stock Award Activity HTML 59K
(Detail)
89: R82 Summary of Restricted Stock Unit Activity (Detail) HTML 59K
103: R83 Summary of Stock Appreciation Rights Activity HTML 56K
(Detail)
63: R84 Summary of Employee Stock Purchase Plan Activity HTML 42K
and Expense (Detail)
26: R85 Summary of Stock-Based Compensation Expense by HTML 43K
Function Included within Consolidated Statements
of Operations and Comprehensive Loss (Detail)
86: R86 Summary of Stock-Based Compensation Expense by HTML 45K
Grant Type Included within Consolidated Statements
of Operations and Comprehensive Loss (Detail)
100: R87 401 (K) PLAN - Additional Information (Detail) HTML 47K
68: R88 Summary of Other (Loss) Income (Detail) HTML 53K
25: R89 Summary of Loss before Provision for Income Taxes HTML 47K
by Jurisdiction (Detail)
42: R90 Summary of Provision for Income Taxes (Detail) HTML 70K
56: R91 Reconciliation Between Effective Tax Rate and HTML 65K
Federal Income Tax Rate (Detail)
123: R92 Income Taxes - Additional Information (Detail) HTML 94K
79: R93 Analysis of Deferred Tax Assets and Liabilities HTML 72K
(Detail)
45: R94 Reconciliation of Beginning and Ending Amount of HTML 45K
Unrecognized Tax Benefits (Detail)
59: R95 Leases - Additional Information (Detail) HTML 46K
126: R96 Summary of Lease Costs Recognized Under Topic 842 HTML 51K
and Other Information Pertaining to Operating
Leases (Detail)
82: R97 Summary of Maturities of Lease Liabilities and HTML 63K
Reconciliation of Lease Liabilities Recognized
Under Topic 842 (Detail)
46: R98 Summary of Aggregate Future Minimum HTML 55K
Non-Cancellable Commitments under Leases (Detail)
54: R99 Basic and Diluted Net Loss Per Share (Detail) HTML 51K
106: R100 Basic and Diluted Net Loss Per Share HTML 48K
(Parenthetical) (Detail)
92: R101 Commitments and Contingencies - Additional HTML 109K
Information (Detail)
21: R102 Summary of Non-Cancelable Contractual Obligations HTML 47K
Arising From Long-term Contractual Arrangements
(Detail)
62: R103 Subsequent Event - Additional Information HTML 38K
(Details)
104: R104 Financial Information by Quarter (Detail) HTML 100K
96: XML IDEA XML File -- Filing Summary XML 232K
40: XML XBRL Instance -- srpt-10k_20191231_htm XML 5.81M
108: EXCEL IDEA Workbook of Financial Reports XLSX 145K
17: EX-101.CAL XBRL Calculations -- srpt-20191231_cal XML 342K
18: EX-101.DEF XBRL Definitions -- srpt-20191231_def XML 936K
19: EX-101.LAB XBRL Labels -- srpt-20191231_lab XML 2.10M
20: EX-101.PRE XBRL Presentations -- srpt-20191231_pre XML 1.60M
16: EX-101.SCH XBRL Schema -- srpt-20191231 XSD 330K
116: JSON XBRL Instance as JSON Data -- MetaLinks 537± 883K
105: ZIP XBRL Zipped Folder -- 0001564590-20-006769-xbrl Zip 863K
 | Download this zipped .zip folder |
| Files: | gbl2prem10b0000001.jpg gbl2prem10b0000002.jpg srpt-10k_20191231.htm srpt-20191231.xsd srpt-20191231_cal.xml srpt-20191231_def.xml srpt-20191231_lab.xml srpt-20191231_pre.xml srpt-ex1051_473.htm srpt-ex1052_472.htm srpt-ex1053_468.htm srpt-ex1054_471.htm srpt-ex1055_470.htm srpt-ex1056_469.htm srpt-ex1057_467.htm srpt-ex211_9.htm srpt-ex231_11.htm srpt-ex311_6.htm srpt-ex312_7.htm srpt-ex321_10.htm srpt-ex322_8.htm srpt-ex44_474.htm |
As Of Filer Filing For·On·As Docs:Size Issuer Filing Agent 3/28/24 Sarepta Therapeutics, Inc. S-8 POS 3/28/24 4:220K Donnelley … Solutions/FA 3/28/24 Sarepta Therapeutics, Inc. S-8 POS 3/28/24 4:220K Donnelley … Solutions/FA 3/28/24 Sarepta Therapeutics, Inc. S-8 POS 3/28/24 4:220K Donnelley … Solutions/FA 3/28/24 Sarepta Therapeutics, Inc. S-8 POS 3/28/24 4:220K Donnelley … Solutions/FA 2/28/24 Sarepta Therapeutics, Inc. 10-K 12/31/23 119:18M Donnelley … Solutions/FA 2/28/23 Sarepta Therapeutics, Inc. 10-K 12/31/22 119:23M Donnelley … Solutions/FA 3/02/22 Sarepta Therapeutics, Inc. S-3ASR 3/02/22 4:438K Donnelley … Solutions/FA 3/01/22 Sarepta Therapeutics, Inc. 10-K 12/31/21 121:20M Donnelley … Solutions/FA 3/01/21 Sarepta Therapeutics, Inc. 10-K 12/31/20 124:22M ActiveDisclosure/FA |